Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe.

Shawarira-Bote S, Shamu T, Chimbetete C.

BMC Infect Dis. 2019 Aug 13;19(1):715. doi: 10.1186/s12879-019-4332-5.

2.

Sexually transmitted infections, the silent partner in HIV-infected women in Zimbabwe.

Lowe S, Mudzviti T, Mandiriri A, Shamu T, Mudhokwani P, Chimbetete C, Luethy R, Pascoe M.

South Afr J HIV Med. 2019 Jan 23;20(1):849. doi: 10.4102/sajhivmed.v20i1.849. eCollection 2019.

3.

Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting: A Retrospective Cohort Study.

Mudzviti T, Shamu T, Chimbetete C, Munengerwa T, Bote S, Pascoe M.

Drugs Real World Outcomes. 2019 Mar;6(1):37-42. doi: 10.1007/s40801-019-0147-3.

4.

Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe.

Sovershaeva E, Shamu T, Wilsgaard T, Bandason T, Flægstad T, Katzenstein D, Ferrand RA, Odland J.

Int J Infect Dis. 2019 Jan;78:65-71. doi: 10.1016/j.ijid.2018.10.019. Epub 2018 Oct 31.

5.

HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe.

Chimbetete C, Katzenstein D, Shamu T, Spoerri A, Estill J, Egger M, Keiser O.

Open Forum Infect Dis. 2018 Feb 2;5(2):ofy005. doi: 10.1093/ofid/ofy005. eCollection 2018 Feb.

6.

Accelerating Discovery of Functional Mutant Alleles in Cancer.

Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, Sumer SO, Kundra R, Razavi P, Li BT, Reales DN, Socci ND, Jayakumaran G, Zehir A, Benayed R, Arcila ME, Chandarlapaty S, Ladanyi M, Schultz N, Baselga J, Berger MF, Rosen N, Solit DB, Hyman DM, Taylor BS.

Cancer Discov. 2018 Feb;8(2):174-183. doi: 10.1158/2159-8290.CD-17-0321. Epub 2017 Dec 15.

7.

Outcomes of an HIV cohort after a decade of comprehensive care at Newlands Clinic in Harare, Zimbabwe: TENART cohort.

Shamu T, Chimbetete C, Shawarira-Bote S, Mudzviti T, Luthy R.

PLoS One. 2017 Oct 24;12(10):e0186726. doi: 10.1371/journal.pone.0186726. eCollection 2017.

8.

Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans.

Musingwini TV, Zhou DT, Mhandire D, Duri K, Gomo E, Oktedalen O, Chimukangara B, Shamu T, Shawarira-Bote S, Dandara C, Stray-Pedersen B.

Open Microbiol J. 2017 Apr 28;11:45-52. doi: 10.2174/1874285801711010045. eCollection 2017.

9.

New-onset type 2 diabetes mellitus among patients receiving HIV care at Newlands Clinic, Harare, Zimbabwe: retrospective cohort analysis.

Chimbetete C, Mugglin C, Shamu T, Kalesan B, Bertisch B, Egger M, Keiser O.

Trop Med Int Health. 2017 Jul;22(7):839-845. doi: 10.1111/tmi.12896. Epub 2017 Jun 8.

10.

HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.

Chimukangara B, Varyani B, Shamu T, Mutsvangwa J, Manasa J, White E, Chimbetete C, Luethy R, Katzenstein D.

J Virol Methods. 2017 May;243:151-157. doi: 10.1016/j.jviromet.2016.11.010. Epub 2016 Nov 25.

11.

Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.

Mhandire D, Lacerda M, Castel S, Mhandire K, Zhou D, Swart M, Shamu T, Smith P, Musingwini T, Wiesner L, Stray-Pedersen B, Dandara C.

OMICS. 2015 Sep;19(9):553-62. doi: 10.1089/omi.2015.0104.

12.

Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.

Boender TS, Hoenderboom BM, Sigaloff KC, Hamers RL, Wellington M, Shamu T, Siwale M, Labib Maksimos EE, Nankya I, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Ondoa P, Rinke de Wit TF.

Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656. Epub 2015 Aug 3.

PMID:
26240203
13.

Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe.

Ondoa P, Shamu T, Bronze M, Wellington M, Boender TS, Manting C, Steegen K, Luethy R, Rinke de Wit T.

Biomed Res Int. 2014;2014:102598. doi: 10.1155/2014/102598. Epub 2014 Jun 15.

14.

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.

Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers CL.

Nat Med. 2013 Aug;19(8):1023-9. doi: 10.1038/nm.3216. Epub 2013 Jun 30.

15.

Monitoring of early warning indicators for HIV drug resistance in antiretroviral therapy clinics in Zimbabwe.

Dzangare J, Gonese E, Mugurungi O, Shamu T, Apollo T, Bennett DE, Kelley KF, Jordan MR, Chakanyuka C, Cham F, Banda RM.

Clin Infect Dis. 2012 May;54 Suppl 4:S313-6. doi: 10.1093/cid/cir1014.

16.

Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.

Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL.

PLoS One. 2012;7(4):e34414. doi: 10.1371/journal.pone.0034414. Epub 2012 Apr 11.

17.

Visualization of the interstitial cells of cajal (ICC) network in mice.

Chen Y, Shamu T, Chen H, Besmer P, Sawyers CL, Chi P.

J Vis Exp. 2011 Jul 27;(53). pii: 2802. doi: 10.3791/2802.

18.

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.

Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL.

Nature. 2010 Oct 14;467(7317):849-53. doi: 10.1038/nature09409. Epub 2010 Oct 3.

Supplemental Content

Support Center